Skip to main content
. 2022 Jul 27;145(8):2834–2848. doi: 10.1093/brain/awab481

Figure 5.

Figure 5

CSF t-tau biomarker concentrations and their diagnostic performance in progressive supranuclear palsy. (A) Box plots presenting CSF concentrations of Innotest t-tau, in-house MR, NTA and NTB t-tau in progressive supranuclear palsy (PSP). (B) AUC from ROC analysis presenting diagnostic accuracies of the tau biomarkers to distinguish between progressive supranuclear palsy and controls. (C) Correlation matrix showing Spearman’s correlations for all measured t-tau and p-tau concentrations in progressive supranuclear palsy. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns = non-significant.